Journal
JOURNAL OF CONTROLLED RELEASE
Volume 140, Issue 3, Pages 294-300Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2009.04.024
Keywords
Polymeric micelle; Drug solubilization; Combination drug therapy; Cremophor EL; Heat shock protein 90 inhibitor
Funding
- NIAID NIH HHS [R01 AI043346, R01 AI043346-12] Funding Source: Medline
Ask authors/readers for more resources
Current clinical and preclinical anticancer formulations are limited by their use of toxic excipients and stability issues upon combining different drug formulations. We have found that poly(ethylene glycol)-block-poly(D,L lactic acid) (PEG-b-PLA) micelles can deliver multiple poorly water-soluble drugs at clinically relevant doses. Paclitaxel (PTX), etoposide (ETO), docetaxel (DCTX) and 17-allylamino-17-demethyoxygeldanamycin (17-AAG) were solubilized individually in PEG-6-PLA micelles. Combinations of PTX/17-AAG, ETO/17-AAG, DCTX/17-AAG and PTX/ETO/17-AAG were also solubilized in PEG-6-PLA micelles. PEG-6-PLA micelles were characterized in terms of drug loading, size, stability and drug release. All anticancer agents in all combinations were all solubilized at the level of mg/mL and were stable for 24 h in the 2- and 3-drug combination PEG-b-PLA micelles. The stability of the 2- and 3-drug combination PEG-6-PLA micelles was due to the presence of 17-AAG. In vitro, t(1/2) values for 2- and 3-drug combination PEG-b-PLA micelles spanned 1-5 h. PEG-6-PLA micelles offer a promising alternative for combination drug therapy without formulation related side effects. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available